Health Care Drops as Mega-Caps and Higher Yields Weigh on XLV

On Wednesday, September 30, Health Care Select Sector SPDR Fund (XLV), an exchange-traded fund tracking the sector, closed -1.3% as heavy selling in the largest healthcare companies weighed on the group. Breadth across the sector deteriorated, with only 12.5% of its stocks advancing during the session. The cap-weighted sector fell further than its equal-weighted counterpart, closing -1.4% compared to -1.0%. That gap shows that mega-cap healthcare names drove the bulk of the session's losses. Macroeconomic pressure contributed to the weakness across stocks, as stronger economic data lifted benchmark Treasury yields and weighed on the broader market.

Declines were visible across major drugmakers and biotechnology firms. Moderna Inc was the sector's weakest performer, closing -5.4%. Gainers were rare, with Veeva Systems Inc Class A finishing +2.5% and Baxter International Inc finishing +2.3%. Encouraging pipeline updates did little to alter the session's tone. Merck presented favorable mid-stage trial results for tulisokibart, an investigational treatment for moderate to severe skin inflammation, while Regeneron completed an early-stage safety trial for its experimental blood clotting candidate ALN-F1202.

Healthcare lagged the wider market on a day when 3 of the 11 sectors rose. With the fund closing at $168.44, its one-month move stands at -1.2%. Even with that near-term pause, longer-term performance remains solid. XLV is up +17.4% over the past 100 sessions, +14.0% across the past six months, and +21.0% over the trailing twelve months.

Despite the day's weakness, high-quality companies represent 52.2% of the fund's graded weight in names graded A or B. EasyAlpha's historical research shows that companies graded A or B have maintained stronger fundamentals and experienced smaller drawdowns on average than those graded D or E.